Perspectives on antithrombotic agents: From unfractionated heparin to new antithrombotics

Haematologica

Volumn 87, Issue 7, 2002, Pages 757-770

  Agnelli, Giancarlo ^a   Sonaglia, Francesco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Acute coronary syndromes; Direct antithrombins; Low molecular weight heparins; Pentasaccharide; Unfractionated heparin; Venous thromboembolism

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTISTASIN; ANTITHROMBIN; ARDEPARIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NADROPARIN; NEMATODE ANTICOAGULANT PROTEIN C2; PENTASACCHARIDE; REVIPARIN; STREPTOKINASE; TICK ANTICOAGULANT PEPTIDE; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN; BLOOD CLOTTING FACTOR; FIBRINOLYTIC AGENT; SERINE PROTEINASE INHIBITOR;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPOLYMERIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; OSTEOPOROSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; DRUG ANTAGONISM; POSTOPERATIVE COMPLICATION; REVIEW; THROMBOSIS;

BLOOD COAGULATION FACTORS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POSTOPERATIVE COMPLICATIONS; SERINE PROTEINASE INHIBITORS; THROMBOSIS;

EID: 0036073158     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Prevention of venous thromboembolism
2. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery
3. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial
4. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis
5. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative study
6. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
7. Efficacy and tolerance of fraxiparin in the prevention of deep vein thrombosis in general surgery performed with medullar conduction anesthesia
8. Efficacy and safety of a low-molecularweight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial
9. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
10. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer
11. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement
12. Twostep warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding
13. Low-molecularweight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
14. Low molecular weight heparin in the prevention of perioperative thrombus
15. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial
16. Randomized trial of a low molecular weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep vein thrombosis after elective hip surgery
17. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty
18. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials
19. Prevention of deep vein thrombosis after major knee surgery: A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo
20. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin
21. Efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of deep venous thrombosis after elective knee arthroplasty
22. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin
23. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery
24. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for prevention of venous thromboembolism after total knee replacement surgery: A double-blind, dose-ranging study
25. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation
26. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement?
27. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture
28. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study
29. Comparative double-blind study of two dosage regimens of low-molecular weight heparin in elderly patients with a fracture of the neck of the femur
30. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures
31. Thromboprophylaxis in hip fracture surgery: A pilot study comparing danaparoid, enoxaparin and dalteparin
32. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials
33. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review
34. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery
35. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery
36. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
37. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
38. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
39. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
40. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
41. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)
42. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216)
43. A randomised trial of low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study
44. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
45. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
46. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
47. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
48. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
49. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
50. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
51. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire
52. Antithrombotic agents in coronary artery disease
53. Clinical status of direct thrombin inhibitors
54. Low-molecular-weight heparins in the management of unstable angina
55. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during instability in coronary artery disease (FRISC) study group
56. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
57. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)
58. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
59. Enoxaparin for the acute and chronic management of unstable angina/non Q wave myocardial infarction. Results of the TIMI 11B
60. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
61. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
62. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin III, but is susceptible to inactivation by antithrombin-independent inhibitors
63. Cloning and expression of a cDNA coding for the anticoagulant hirudin from bloodsucking leech, Hirudo medicinalis
64. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery
65. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicentre prospective dose-ranging randomized trial
66. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
67. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
68. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
69. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial
70. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK)
71. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
72. Impact of hirudin on mortality and reinfarction in patients with acute coronary syndromes: A prospective meta-analysis of the GUSTO IIb and TIMI 9B trials
73. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
74. Heparin-induced thrombocytopenia: Pathogenesis and treatment
75. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
76. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
77. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients
78. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery
79. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
80. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial
81. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
82. Pharmacodynamic properties of ximelagatran, a prodrug of the direct thrombin inhibitor melagatran intended for oral use
83. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery
84. METHRO II: Dose-response study of the novel oral, direct thrombin inhibitor, H/376/95, and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or knee replacement
85. The oral direct thrombin inhibitor ximelagatran (formerly H 376/95) and its subcutaneous form melagatran compared with enoxaparin as thromboprophylaxis after total hip or total knee replacement
86. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement
87. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide ORG31540/SR90107A, versus low-molecular-weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The EPHESUS study
88. Efficacy of the first synthetic factor Xa inhibitor, Pentasaccharide ORG31540/SR90107A, versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The Pentathlon 2000 Study
89. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. Steering Committee of the Pentasaccharide in Major Knee Surgery Study
90. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study
91. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation
92. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study
93. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement